Prime Highlights:

• Aurobindo Pharma is using Europe as a major growth market, expanding its presence across nine EU countries and the UK.
• The company has broadened its product portfolio from generics to include biosimilars, injectables, and inhalers, with recent regulatory approvals in Europe and the UK.

Key Facts:

• Aurobindo ranks among the top 10 pharmaceutical companies in eight of the nine European countries where it operates.
• Its UK subsidiary, CuraTeQ Biologics, received approval to market Dazublys, a biosimilar of trastuzumab for treating certain breast and stomach cancers.

Background:

Aurobindo Pharma, a top Indian pharmaceutical company, is using Europe as a key market for its international growth. The company has established a presence in the UK and nine European Union markets, positioning itself as a high-growth player in the region.

Venugopalan Muralidharan, CEO of Aurobindo’s Europe business, told ET Now that the company has steadily increased its product portfolio and built teams that are well attuned to the diverse European market landscape.

“From its beginnings as a plain vanilla generics manufacturer, Aurobindo now offers a wide range of products including biosimilars, injectables, and inhalers,” Muralidharan said. The company’s portfolio growth is supported through a combination of in-house development and in-licensing initiatives.

In recent developments, Aurobindo has received three approvals from the European Medicines Agency (EMA) and one approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its biosimilars. Aurobindo’s UK subsidiary, CuraTeQ Biologics, recently got approval to sell Dazublys, a biosimilar of trastuzumab, used to treat some breast and stomach cancers.

Europe offers good growth opportunities, but Muralidharan said the company faces challenges like pricing pressure, currency changes, and different regulations. Still, Aurobindo is among the top 10 pharmaceutical companies in eight of the nine European countries where it works, including France, Germany, Spain, Portugal, Italy, the Netherlands, Belgium, Poland, Malta, and the UK.

Aurobindo’s growth in Europe is part of its bigger plan to expand in many regions and product areas, making it a strong player in the global pharmaceutical market.